IT1211469B - Idrato cristallino di acido 7 beta 72 2 amminotiazol 4 il 4 carbossi but 2 enoilammino 3 cefem 4 carbossilico procedimento per il suo ottenimento confezione per capsule di gelatina contenente detto idrato eprocedimento per l ottenimento di detta composizione - Google Patents

Idrato cristallino di acido 7 beta 72 2 amminotiazol 4 il 4 carbossi but 2 enoilammino 3 cefem 4 carbossilico procedimento per il suo ottenimento confezione per capsule di gelatina contenente detto idrato eprocedimento per l ottenimento di detta composizione

Info

Publication number
IT1211469B
IT1211469B IT8767566A IT6756687A IT1211469B IT 1211469 B IT1211469 B IT 1211469B IT 8767566 A IT8767566 A IT 8767566A IT 6756687 A IT6756687 A IT 6756687A IT 1211469 B IT1211469 B IT 1211469B
Authority
IT
Italy
Prior art keywords
procedure
hydrate
enoilammino
carbossi
amminothiazol
Prior art date
Application number
IT8767566A
Other languages
English (en)
Other versions
IT8767566A0 (it
Inventor
Hamashima Kyoji Minami Yoshio
Kawata Teruo Sakamoto Kyozo
Takeda Yusuke Suzuki Toyohiko
Tujikawa Masanori
Original Assignee
Shionogi & Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from JP61156954A external-priority patent/JP2544113B2/ja
Priority claimed from JP21626086A external-priority patent/JPH0717651B2/ja
Application filed by Shionogi & Co filed Critical Shionogi & Co
Publication of IT8767566A0 publication Critical patent/IT8767566A0/it
Application granted granted Critical
Publication of IT1211469B publication Critical patent/IT1211469B/it

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D501/00—Heterocyclic compounds containing 5-thia-1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula:, e.g. cephalosporins; Such ring systems being further condensed, e.g. 2,3-condensed with an oxygen-, nitrogen- or sulfur-containing hetero ring
    • C07D501/14—Compounds having a nitrogen atom directly attached in position 7
    • C07D501/16—Compounds having a nitrogen atom directly attached in position 7 with a double bond between positions 2 and 3
    • C07D501/20—7-Acylaminocephalosporanic or substituted 7-acylaminocephalosporanic acids in which the acyl radicals are derived from carboxylic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/542—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/545—Compounds containing 5-thia-1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula:, e.g. cephalosporins, cefaclor, or cephalexine

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Cephalosporin Compounds (AREA)
IT8767566A 1986-07-02 1987-07-01 Idrato cristallino di acido 7 beta 72 2 amminotiazol 4 il 4 carbossi but 2 enoilammino 3 cefem 4 carbossilico procedimento per il suo ottenimento confezione per capsule di gelatina contenente detto idrato eprocedimento per l ottenimento di detta composizione IT1211469B (it)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP61156954A JP2544113B2 (ja) 1986-07-02 1986-07-02 安定なカプセル製剤
JP21626086A JPH0717651B2 (ja) 1986-09-12 1986-09-12 経口投与用セフアロスポリン水和物結晶

Publications (2)

Publication Number Publication Date
IT8767566A0 IT8767566A0 (it) 1987-07-01
IT1211469B true IT1211469B (it) 1989-11-03

Family

ID=26484565

Family Applications (1)

Application Number Title Priority Date Filing Date
IT8767566A IT1211469B (it) 1986-07-02 1987-07-01 Idrato cristallino di acido 7 beta 72 2 amminotiazol 4 il 4 carbossi but 2 enoilammino 3 cefem 4 carbossilico procedimento per il suo ottenimento confezione per capsule di gelatina contenente detto idrato eprocedimento per l ottenimento di detta composizione

Country Status (27)

Country Link
US (2) US4812561A (it)
KR (1) KR950005302B1 (it)
CN (1) CN1015106B (it)
AR (1) AR243893A1 (it)
AT (1) AT392472B (it)
AU (1) AU594167B2 (it)
BE (1) BE1001691A4 (it)
CA (1) CA1283405C (it)
CH (1) CH672788A5 (it)
DE (1) DE3721913A1 (it)
DK (1) DK161080C (it)
ES (2) ES2004952A6 (it)
FI (1) FI89052C (it)
FR (1) FR2601014B1 (it)
GB (1) GB2192183B (it)
GR (1) GR871014B (it)
HK (1) HK47893A (it)
HU (1) HU200777B (it)
IE (1) IE59613B1 (it)
IL (1) IL83059A (it)
IT (1) IT1211469B (it)
NL (1) NL193136C (it)
NO (1) NO170889C (it)
NZ (1) NZ220764A (it)
PL (1) PL159180B1 (it)
RU (1) RU1829932C (it)
SE (1) SE466257B (it)

Families Citing this family (67)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5089270A (en) * 1990-05-15 1992-02-18 L. Perrigo Company Capsule-shaped tablet
AU674516B2 (en) * 1992-04-30 1997-01-02 Schering Corporation Stable hydrated cephalosporin dry powder for oral suspension formulation
DE69943137D1 (de) * 1998-10-27 2011-02-24 Westlake Longview Corp Verfahren zur Olefinpolymerisation, Polyethylene und daraus hergestellte Folien und Artikel
US6565882B2 (en) * 2000-02-24 2003-05-20 Advancis Pharmaceutical Corp Antibiotic composition with inhibitor
US6544555B2 (en) * 2000-02-24 2003-04-08 Advancis Pharmaceutical Corp. Antibiotic product, use and formulation thereof
AT412213B (de) * 2000-05-30 2004-11-25 Sandoz Ag Verfahren zur trocknung von amoxicillin oder amoxicillin-hältigen, oralen, festen pharmazeutischen zusammensetzungen unter verwendung eines gases mit einer definierten gasfeuchte
US20020068078A1 (en) * 2000-10-13 2002-06-06 Rudnic Edward M. Antifungal product, use and formulation thereof
US6541014B2 (en) * 2000-10-13 2003-04-01 Advancis Pharmaceutical Corp. Antiviral product, use and formulation thereof
US20020197314A1 (en) * 2001-02-23 2002-12-26 Rudnic Edward M. Anti-fungal composition
US7842791B2 (en) * 2002-12-19 2010-11-30 Nancy Jean Britten Dispersible pharmaceutical compositions
JP2006528189A (ja) * 2003-07-21 2006-12-14 アドバンシス ファーマスーティカル コーポレイション 抗生物質産物、その使用法および製剤
CA2533358C (en) * 2003-07-21 2014-03-11 Advancis Pharmaceutical Corporation Antibiotic product, use and formulation thereof
JP2006528190A (ja) * 2003-07-21 2006-12-14 アドバンシス ファーマスーティカル コーポレイション 抗生物質製剤、その使用法及び作成方法
EP1653925A1 (en) * 2003-08-11 2006-05-10 Advancis Pharmaceutical Corporation Robust pellet
CA2535398C (en) 2003-08-12 2013-11-12 Advancis Pharmaceuticals Corporation Antibiotic product, use and formulation thereof
US8246996B2 (en) * 2003-08-29 2012-08-21 Shionogi Inc. Antibiotic product, use and formulation thereof
CA2538064C (en) * 2003-09-15 2013-12-17 Advancis Pharmaceutical Corporation Antibiotic product, use and formulation thereof
AU2004308419B2 (en) * 2003-12-24 2011-06-02 Victory Pharma, Inc. Enhanced absorption of modified release dosage forms
WO2006014427A1 (en) * 2004-07-02 2006-02-09 Advancis Pharmaceutical Corporation Tablet for pulsed delivery
US20110104109A1 (en) * 2005-07-13 2011-05-05 Frank Bennett Tetracyclic indole derivatives and their use for treating or preventing viral infections
US8404697B2 (en) 2005-11-11 2013-03-26 Boehringer Ingelheim International Gmbh Quinazoline derivatives for the treatment of cancer diseases
US8357394B2 (en) 2005-12-08 2013-01-22 Shionogi Inc. Compositions and methods for improved efficacy of penicillin-type antibiotics
US8778924B2 (en) * 2006-12-04 2014-07-15 Shionogi Inc. Modified release amoxicillin products
US8299052B2 (en) * 2006-05-05 2012-10-30 Shionogi Inc. Pharmaceutical compositions and methods for improved bacterial eradication
AR062927A1 (es) * 2006-10-11 2008-12-17 Bayer Healthcare Ag 4- [4-( [ [ 4- cloro-3-( trifluorometil) fenil) carbamoil] amino] -3- fluorofenoxi) -n- metilpiridin-2- carboxamida monohidratada
CN101631773A (zh) 2006-12-22 2010-01-20 先灵公司 治疗或预防hcv和相关病毒感染的4,5-环化吲哚衍生物
MX2009006878A (es) * 2006-12-22 2009-07-07 Schering Corp Derivados indolicos con anillo unido en las posiciones 4,5 para tratar o prevenir infecciones virales por virus de la hepatitis c e infecciones virales relacionadas.
WO2008136815A2 (en) 2006-12-22 2008-11-13 Schering Corporation 5, 6-ring annulated indole derivatives and use thereof
RU2010111551A (ru) 2007-08-29 2011-10-10 Шеринг Корпорейшн (US) Замещенные индольные производные и способы их применения
MX2010002319A (es) * 2007-08-29 2010-03-22 Schering Corp Derivados indolicos 2,3 sustituidos para el tratamiento de infecciones virales.
PE20090994A1 (es) 2007-08-29 2009-08-03 Schering Corp Derivados de azaindol 2,3-sustituidos como agentes antivirales
MX2010005356A (es) * 2007-11-16 2010-05-27 Schering Corp Derivados de indol 3-heterociclico sustituidos y metodos de uso de los mismos.
WO2009064852A1 (en) * 2007-11-16 2009-05-22 Schering Corporation 3-aminosulfonyl substituted indole derivatives and methods of use thereof
WO2009152200A1 (en) * 2008-06-13 2009-12-17 Schering Corporation Tricyclic indole derivatives and methods of use thereof
JP5674661B2 (ja) 2008-08-20 2015-02-25 メルク・シャープ・アンド・ドーム・コーポレーションＭｅｒｃｋ Ｓｈａｒｐ ＆ Ｄｏｈｍｅ Ｃｏｒｐ． エチニル置換ピリジンおよびピリミジン誘導体ならびにそれらのウイルス感染の治療における使用
AR072939A1 (es) 2008-08-20 2010-09-29 Schering Corp Derivados de piridina y pirimidina sustituidas con etenilo y su uso en el tratamiento de infecciones virales
JP5654990B2 (ja) 2008-08-20 2015-01-14 メルク・シャープ・アンド・ドーム・コーポレーションＭｅｒｃｋ Ｓｈａｒｐ ＆ Ｄｏｈｍｅ Ｃｏｒｐ． アゾ置換ピリジンおよびピリミジン誘導体ならびにそれらのウイルス感染の治療における使用
JP5731976B2 (ja) 2008-08-20 2015-06-10 メルク・シャープ・アンド・ドーム・コーポレーションＭｅｒｃｋ Ｓｈａｒｐ ＆ Ｄｏｈｍｅ Ｃｏｒｐ． 置換ピリジン誘導体および置換ピリミジン誘導体ならびにそれらのウイルス感染の治療における使用
US8980920B2 (en) 2009-05-29 2015-03-17 Merck Sharp & Dohme Corp. Antiviral compounds of three linked aryl moieties to treat diseases such as hepatitis C
ES2731901T3 (es) 2009-07-06 2019-11-19 Boehringer Ingelheim Int Proceso para el secado de BIBW2992, de sus sales y de formulaciones farmacéuticas sólidas que comprenden este ingrediente activo
US20120276047A1 (en) 2009-11-25 2012-11-01 Rosenblum Stuart B Fused tricyclic compounds and derivatives thereof useful for the treatment of viral diseases
JP2013515068A (ja) 2009-12-22 2013-05-02 メルク・シャープ・アンド・ドーム・コーポレーション ウイルス性疾患の治療のための縮合三環式化合物およびその使用方法
EP2536410B1 (en) 2010-02-18 2015-09-23 Merck Sharp & Dohme Corp. Substituted pyrimidine derivatives and their use in treating viral infections
MX2012010392A (es) 2010-03-09 2012-10-03 Merck Sharp & Dohme Compuesto de sililo triciclicos fusionados y metodos de uso de los mismos para el tratamiento de enfermedades virales.
WO2011139253A2 (en) 2010-05-04 2011-11-10 Mahmut Bilgic Pharmaceutical compositions comprising ceftibuten
US20140377223A1 (en) 2010-07-26 2014-12-25 Joseph A. Kozlowski Substituted biphenylene compounds and methods of use thereof for the treatment of viral diseases
AU2011314168A1 (en) 2010-09-29 2013-04-04 Merck Sharp & Dohme Corp. Fused tetracycle derivatives and methods of use thereof for the treatment of viral diseases
CN103582420B (zh) 2011-04-13 2016-10-19 默沙东公司 2’-取代的核苷衍生物和使用其治疗病毒病的方法
US9156872B2 (en) 2011-04-13 2015-10-13 Merck Sharp & Dohme Corp. 2′-azido substituted nucleoside derivatives and methods of use thereof for the treatment of viral diseases
WO2013033901A1 (en) 2011-09-08 2013-03-14 Merck Sharp & Dohme Corp. Heterocyclic-substituted benzofuran derivatives and methods of use thereof for the treatment of viral diseases
WO2013033899A1 (en) 2011-09-08 2013-03-14 Merck Sharp & Dohme Corp. Substituted benzofuran compounds and methods of use thereof for the treatment of viral diseases
WO2013033900A1 (en) 2011-09-08 2013-03-14 Merck Sharp & Dohme Corp. Tetracyclic heterocycle compounds and methods of use thereof for the treatment of viral diseases
EP2755981A4 (en) 2011-09-14 2015-03-25 Merck Sharp & Dohme HETEROCYCLIC COMPOUNDS CONTAINING SILYL AND METHODS OF USING THE SAME FOR TREATING VIRAL DISEASES
EP2833874A1 (en) * 2012-04-04 2015-02-11 Mahmut Bilgic Capsule formulations comprising ceftibuten
EP2815743A1 (en) 2013-06-21 2014-12-24 Sanovel Ilac Sanayi ve Ticaret A.S. Ceftibuten formulations
WO2015065817A1 (en) 2013-10-30 2015-05-07 Merck Sharp & Dohme Corp. Pseudopolymorphs of an hcv ns5a inhibitor and uses thereof
US9242965B2 (en) 2013-12-31 2016-01-26 Boehringer Ingelheim International Gmbh Process for the manufacture of (E)-4-N,N-dialkylamino crotonic acid in HX salt form and use thereof for synthesis of EGFR tyrosine kinase inhibitors
CN103948932B (zh) * 2014-04-17 2016-03-16 海南日中天制药有限公司 一种头孢克肟组合物及其制备方法
EP3031450A1 (en) 2014-12-12 2016-06-15 Sanovel Ilac Sanayi ve Ticaret A.S. Ceftibuten capsule compositions
RU2018144043A (ru) 2016-05-13 2020-06-15 Аэромикс, Инк. Кристаллы
CN106397455B (zh) * 2016-08-30 2018-08-31 山东罗欣药业集团恒欣药业有限公司 一种抗感染药物头孢布烯晶体化合物及其组合物
CN106397454B (zh) * 2016-08-30 2018-08-24 山东罗欣药业集团股份有限公司 一种抗感染药物头孢布烯晶型化合物及其组合物
CN106397457A (zh) * 2016-09-21 2017-02-15 临沂草之美医药科技有限公司 一种治疗外科手术感染的药物头孢布烯晶体化合物
CN106432271A (zh) * 2016-09-21 2017-02-22 临沂草之美医药科技有限公司 一种治疗外科手术感染的药物头孢布烯晶体化合物
CN106432270A (zh) * 2016-09-21 2017-02-22 临沂草之美医药科技有限公司 一种制备治疗外科手术感染的药物头孢布烯晶体化合物的方法
CN106432272A (zh) * 2016-09-21 2017-02-22 临沂草之美医药科技有限公司 一种制备治疗外科手术感染的药物头孢布烯晶体化合物的方法
WO2023278945A1 (en) * 2021-07-01 2023-01-05 Qpex Biopharma, Inc. Crystalline forms of ceftibuten

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3819620A (en) * 1972-06-01 1974-06-25 Squibb & Sons Inc 7-(d-alpha-amino-1,4-cyclohexadien-1-ylacet-amido)desacetoxycephalosporanic acid dihydrate
JPS5726692A (en) * 1980-07-22 1982-02-12 Fujisawa Pharmaceut Co Ltd Preparation of stable crystal of salt of ceftizoxime
DE3037997A1 (de) * 1980-10-08 1982-05-13 Bayer Ag (beta) -lactamantibiotika, verfahren zu deren herstellung sowie sie enthaltende mittel
YU44680B (en) * 1982-07-30 1990-12-31 Glaxo Lab Ltd Process for obtaining very pure amorphous form of cephuroxim axetile
AU575854B2 (en) * 1983-10-04 1988-08-11 Shionogi & Co., Ltd. 7beta-(carboxyalkenamido) cephalosporins
AU580855B2 (en) * 1985-03-29 1989-02-02 Shionogi & Co., Ltd. Alkeneamidocephalosporin esters

Also Published As

Publication number Publication date
DK161080B (da) 1991-05-27
FI872903A0 (fi) 1987-07-01
CH672788A5 (it) 1989-12-29
BE1001691A4 (fr) 1990-02-13
GB2192183B (en) 1990-05-16
AR243893A1 (es) 1993-09-30
NO170889B (no) 1992-09-14
HU200777B (en) 1990-08-28
IL83059A (en) 1992-03-29
CN1015106B (zh) 1991-12-18
NL8701507A (nl) 1988-02-01
GB8715064D0 (en) 1987-08-05
US4812561A (en) 1989-03-14
RU1829932C (ru) 1993-07-23
CN87105009A (zh) 1988-03-23
AU594167B2 (en) 1990-03-01
US4933443A (en) 1990-06-12
DK336487A (da) 1988-01-03
DK161080C (da) 1991-11-11
NL193136C (nl) 1998-12-04
HK47893A (en) 1993-05-27
FR2601014A1 (fr) 1988-01-08
FI872903A (fi) 1988-01-03
HUT44257A (en) 1988-02-29
NO872729D0 (no) 1987-06-30
IE59613B1 (en) 1994-03-09
GB2192183A (en) 1988-01-06
NL193136B (nl) 1998-08-03
AU7504087A (en) 1988-01-07
AT392472B (de) 1991-04-10
SE8702705L (sv) 1988-01-03
DK336487D0 (da) 1987-06-30
GR871014B (en) 1987-11-02
CA1283405C (en) 1991-04-23
ATA165887A (de) 1990-09-15
IT8767566A0 (it) 1987-07-01
NZ220764A (en) 1989-09-27
FI89052B (fi) 1993-04-30
SE466257B (sv) 1992-01-20
SE8702705D0 (sv) 1987-06-30
PL159180B1 (pl) 1992-11-30
DE3721913A1 (de) 1988-01-07
FR2601014B1 (fr) 1990-09-14
KR880001670A (ko) 1988-04-26
NO170889C (no) 1992-12-23
IL83059A0 (en) 1987-12-31
PL266567A1 (en) 1988-07-21
FI89052C (fi) 1993-08-10
KR950005302B1 (ko) 1995-05-23
IE871738L (en) 1988-01-02
ES2004952A6 (es) 1989-02-16
NO872729L (no) 1988-01-04
ES2008759A6 (es) 1989-08-01

Similar Documents

Publication Publication Date Title
IT1211469B (it) Idrato cristallino di acido 7 beta 72 2 amminotiazol 4 il 4 carbossi but 2 enoilammino 3 cefem 4 carbossilico procedimento per il suo ottenimento confezione per capsule di gelatina contenente detto idrato eprocedimento per l ottenimento di detta composizione
PT84053B (pt) Processo para a preparacao de derivados do acido n-azabiciclo-indol-carboxilico-(1) substituido e de composicoes farmaceuticas contendo-os
HUT38341A (en) Process for producing benzoic acid derivatives and pharmaceutical compositions containing them
HUT48208A (en) Process for producing heterocyclic analogues of mevalolactone derivatives and pharmaceutical compositions comprising such compounds
HUT44171A (en) Process for producing peroral pharmaceutical compositions with acid sensitive active components
HUT43825A (en) Process for producing quinolon-carboxylic acid derivatives and pharmaceutical compositions containing them
HUT36455A (en) Process for preparing indole derivatives and pharmaceutical compositions containing such compounds
HUT42101A (en) Process for preparing stomatostatine derivatives and pharmaceutical compositions containing such compounds
PT85886A (en) Process for producing 1-tertiary-alkyl-substituted naphthrydine-carboxylic and quinoline-carboxylic acids and pharmaceutic compositions containing them and starting compounds
PT79714B (en) Process for preparing novel derivatives of guanine and of pharmaceutical compositions containing the same
HUT37152A (en) Process for producing ceph-3-eme-4-carboxylic acid derivatives and pharmaceutical compositions containing them
PT77957A (en) Process for preparing phenothiazone derivatives their analogs and pharmaceutical compositions containing them
HUT40447A (en) Process for preparing substituted alpha-amino acids and pharmaceutical compositions containing such compounds
HUT36482A (en) Process for preparing n6-1/1- or 2-benzocycloalkyl/-andenozine derivatives and pharmaceutical compositions containing such compounds
PT76523B (en) Process for preparing phenoxyalkylcarboxylic acid derivatives and of pharmaceutical compositions containing the same
IL72471A (en) Pharmaceutical compositions containing 2-(hetero)aryl-quinoline-4-carboxylic acid and derivatives thereof,certain such novel compounds and their preparation
PT75100B (en) Process for the preparation of soft gelatine capsules containing ergod alcaloid
HUT46534A (en) Process for producing pharmaceutical composition containing benzopirane-2-carboxylik acid derivative
HUT45398A (en) Process for production of lyophilized medical compositions containing derivatives of phenil-quinoline-carbonic acid
IL73881A (en) Preparation of 16-phenoxy-and 16-substituted phenoxy-4,5,13-prostatrienoic acid derivatives,some such novel compounds and pharmaceutical compositions containing them
PT86297A (en) Process for preparing aryloxybenzeneacetic acid derivatives and of pharmaceutical compositions containing the same
HUT36807A (en) Process for preparing new tetrazolyl derivatives and pharmaceutical compositions containing such compounds
PT76557B (en) Process for preparing furan derivatives and addition salts thereof and of pharmaceutical compositions containing the same
PL250031A1 (en) Process for preparing derivatives of 6- -1-hydroxyethylpenemo-2-carboxylic-3 acid
PT86455A (en) Process for the preparation of pharmaceutical compositions containing pyranoquinoline derivatives

Legal Events

Date Code Title Description
ITCP Complementary protection certificate

Free format text: CCP 85

MEDD Supplementary protection certificate for pharmaceutical products: granted

Free format text: CCP 85, 19920402; SHIONOGI SEIYAKU KABUSHIKI KAISHA ( SHIONOGI & CO. LTD.)

TA Fee payment date (situation as of event date), data collected since 19931001

Effective date: 19950731